STAGE IV LUNG CANCER AJCC V8

This study is testing whether a drug called cabozantinib, alone or combined with an immunotherapy drug (nivolumab), works better than standard chemotherapy for people with a specific type of advanced lung cancer that has worsened after initial treatment. It involves about 117 par…

This study is testing whether combining a cancer vaccine (CIMAvax) with immunotherapy drugs (nivolumab or pembrolizumab) is safe and effective for people with advanced non-small cell lung cancer or squamous head and neck cancer. The goal is to help the body's immune system better…

This study is testing if adding a new drug called berzosertib to a standard three-drug treatment works better for people with advanced squamous cell lung cancer. The goal is to control the cancer, slow its growth, and help patients live longer. Researchers will compare the four-d…

This early-stage study is testing the safety and best dose of an experimental drug called berzosertib when given alongside standard whole brain radiation therapy. The goal is to see if the drug combination works better than standard care to control cancer that has spread from the…

This study is testing a focused form of radiation, called stereotactic radiosurgery (SRS), for patients with small cell lung cancer that has spread to the brain. The goal is to see if targeting only the specific tumor spots, instead of radiating the whole brain, can better preser…

This is an early-stage safety study testing a new drug called BAY 1895344 when given with standard chemotherapy drugs (cisplatin with or without gemcitabine). The main goals are to find the safest dose and understand the side effects in people with advanced solid tumors that have…

This study tested a personalized approach for treating advanced lung cancer that had stopped responding to standard drugs. Doctors analyzed each patient's specific tumor mutations and assigned them to one of several targeted drug combinations or chemotherapy. The goal was to see …

This trial is testing a combination of three drugs (niraparib, temozolomide, and atezolizumab) to see if they work better together to control advanced cancers. The study first finds the safest dose, then compares the three-drug combo to a single drug for patients with extensive-s…

This early-stage trial is testing a combination of two oral drugs, sapanisertib and telaglenastat, in patients with advanced non-small cell lung cancer that has spread and stopped responding to standard treatments. The main goals are to find the safest and most effective dose and…

This early-stage study is testing a combination of four drugs for people with a specific type of advanced lung cancer (ALK-positive). The main goals are to find the safest dose of the new drug, ensartinib, when given with three other cancer drugs, and to see if this combination h…

This early-stage study is testing a new combination treatment for advanced non-small cell lung cancer that has spread or returned. Researchers are combining a drug made from vitamin A (ATRA) with an immunotherapy drug (atezolizumab) to see if it is safe and to find the best dose.…

This early-stage trial is testing a new way to give an immunotherapy drug called nivolumab to patients with melanoma or lung cancer that has spread to the membranes surrounding the brain and spinal cord. The goal is to see if giving the drug directly into the spinal fluid, along …

This study is for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation). It tests if taking the targeted drug osimertinib for 6-12 weeks, then adding focused radiation therapy or surgery to remaining tumors, works better at keeping the…

This early-stage study aims to find the safest and most effective dose of a new drug, M6620, when given with the chemotherapy drug irinotecan. It is for adults with advanced solid tumors, like certain colorectal, pancreatic, or lung cancers, that have spread or cannot be removed …

This early-stage trial is testing the safety and best dose of a two-drug combination for people with a specific type of advanced lung cancer. The study is for adults whose EGFR-mutant non-small cell lung cancer has continued to grow despite prior targeted therapy. Researchers wan…

This study is for people with advanced non-small cell lung cancer that has low levels of a marker called PD-L1. It compares the standard immunotherapy treatment (with or without chemo) to the same treatment plus a short course of radiation. The goal is to see if adding radiation …

This study is testing whether a lung cancer immunotherapy drug can be safely and effectively given at home by a visiting nurse, with most doctor visits done remotely via video call. It involves patients with non-small cell lung cancer who are eligible for the drug atezolizumab. T…

This study is testing a new, faster way to give radiation after surgery for non-small cell lung cancer. Instead of weeks of daily treatments, doctors give one powerful, highly focused dose to try to kill any leftover cancer cells while aiming to spare healthy lung tissue. The mai…

This early-stage study is testing whether adding an experimental drug called minnelide to an existing lung cancer medication (osimertinib) is safe and might help patients whose cancer has continued to grow. The trial is for adults with advanced non-small cell lung cancer that has…

This early study is testing a two-part treatment for advanced non-small cell lung cancer with a specific genetic change (ALK). First, patients take a targeted drug (brigatinib) to shrink tumors. Then, they receive focused radiation or surgery to try to eliminate any remaining can…

This study is comparing two standard ways to treat small lung tumors: a minimally invasive procedure that uses microwave energy to heat and destroy the tumor, and a small surgery to cut it out. Researchers want to see which method is safer, more effective at keeping the cancer fr…

This study is testing whether combining two drugs, atezolizumab and cobimetinib, can help control advanced non-small cell lung cancer that has spread or returned and has stopped responding to a common type of immunotherapy. The trial aims to see if this combination can shrink tum…

This study is testing if adding a drug called bevacizumab to a standard lung cancer drug (osimertinib) works better to control cancer that has spread to the brain. It is for adults with a specific type of advanced lung cancer (EGFR-positive non-small cell lung cancer) who have no…

This study is for people with stage IV non-small cell lung cancer. It tests if adding local treatments like surgery or radiation to a two-drug immunotherapy regimen helps patients live longer than immunotherapy alone. The trial enrolled 339 patients who had not progressed after a…

This study is testing if adding a new drug called pevonedistat to two standard chemotherapy drugs (carboplatin and paclitaxel) works better for people with advanced non-small cell lung cancer. It is for adults whose cancer has gotten worse after treatment with immunotherapy. The …

This early-stage study is testing a new combination of two drugs, sonidegib and pembrolizumab, for people with advanced solid tumors that have spread. The main goals are to find the safest dose of the combination and see if it helps shrink or control the cancer. The study is enro…

This is a small, early-stage safety study testing a combination of two cancer drugs, nivolumab and cabozantinib, in people living with HIV who have advanced solid tumors. The main goal is to see if the two-drug combination is safe and tolerable for this specific patient group. Re…

This is a first-in-human study to find a safe dose of an experimental pill called WSD0922-FU for people with aggressive brain tumors or lung cancer that has spread to the brain. The pill is designed to block a specific protein (EGFR) that drives these cancers and may be able to r…

This early-stage study is testing a new type of cell therapy for people with advanced non-small cell lung cancer that has spread and no longer responds to standard immunotherapy. Researchers are giving patients specially modified immune cells (called NK cells) taken from umbilica…

This early-stage trial is testing a combination of two oral drugs, osimertinib and telaglenastat, for adults with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation) and has stopped responding to standard targeted therapy. The main goals are to …

This study is testing an oral drug called selpercatinib for people with advanced non-small cell lung cancer that has a specific genetic change called a RET fusion. The goal is to see how well the drug shrinks tumors and controls the cancer by blocking the abnormal protein driving…

This trial is testing whether adding a new drug called LY3295668 to an existing lung cancer drug (osimertinib) can help control cancer that has stopped responding to standard treatment. It involves 32 adults with a specific type of advanced lung cancer (EGFR-mutant non-small cell…

This study is testing a combination of two drugs, trametinib and pembrolizumab, for people with advanced non-small cell lung cancer that has come back or spread after previous treatments. The goal is to see if the drugs work better together to control the cancer and to find the s…

This large, late-stage trial aims to find the best way to combine immunotherapy and chemotherapy for patients with advanced non-squamous lung cancer. It will compare starting with immunotherapy alone versus starting with both treatments together, and test different approaches if …

This study is testing a new combination of treatments for people with extensive-stage small cell lung cancer who haven't had treatment yet. It combines a targeted drug (olaparib), an immunotherapy drug (durvalumab), standard chemotherapy, and radiation. The goal is to see if this…

This early-phase study is testing a combination of two drugs, brigatinib and bevacizumab, for patients with a specific type of advanced lung cancer (ALK-positive) that has worsened despite prior targeted therapy. The main goals are to find the safest dose and understand the side …

This study is testing a new combination of three drugs for people with advanced non-small cell lung cancer that has spread or come back after standard treatments failed. The goal is to see if mixing an immunotherapy drug, a drug that blocks tumor blood supply, and a chemotherapy …

This study is testing an experimental pill called AMG 510 for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. The pill is designed to block this specific mutation, which can drive cancer growth, in patients whose cancer has wor…

This study is testing whether a drug called anamorelin can improve appetite and help stop weight loss in people with advanced non-small cell lung cancer. Participants will take either the drug or a placebo pill daily for nine weeks. Researchers will interview patients about their…

This study is testing a simple conversation tool designed to help people with lung cancer better understand their treatment options and participate in decisions with their doctors. The tool is being evaluated at two cancer centers with 98 participants who have non-small cell lung…

This study is testing whether a special program led by nurses can help people with advanced lung or gynecologic cancer cope with intense fears about their illness getting worse. Participants will have five short video sessions over six weeks to learn worry management skills, set …

This study is testing an online support program designed to help women with lung cancer feel better emotionally and manage their symptoms. Participants are assigned to either a group learning mindfulness and coping skills or a group receiving educational information about lung ca…

This study aims to see if doctors can reliably measure the amount of a common chemotherapy drug, paclitaxel, in a patient's blood. The goal is to learn if tracking these drug levels can help doctors adjust doses to better fight cancer while reducing a major side effect: nerve dam…

This study is testing whether a short educational video can help patients with advanced cancer better understand tumor genomic testing. It involves 243 adults with metastatic breast or lung cancer who are already scheduled for this type of testing. Researchers will measure if wat…